Moonshot AI redirects Kimi toward science
The Decoder reports that Moonshot AI is redirecting its Kimi language models from coding toward biology, chemistry, and pharmaceutical research because the company sees diminishing returns in coding. Moonshot AI international director Giacomo Ficari said at the Web Summit in Lisbon that science demands smarter models than law, finance, or code. DP Technology is integrating Kimi K3.1 Pro into its research assistant BioMaster. In one partner test, the system analyzed gene data from 3,696 mouse pancreatic cells and flagged 100 candidate genes in 90 minutes, compared with an estimated four hours of human work. The report also notes that leading models produced verifiable proofs on TCSExam but solved no open conjectures alone. A June Citi survey of 50 US research leaders found that 24% expected AI to noticeably improve drug-development success rates.
The redirection marks a strategic expansion of Kimi into biology, chemistry, and pharmaceutical research. However, the report says fully independent AI breakthroughs remain distant, and only a minority of surveyed research leaders expect noticeable improvements in drug-development success rates.
Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten
Nov 16, 2026
Because Moonshot AI sees diminishing returns in coding, the Beijing startup is redirecting its Kimi language models toward biology, chemistry, and pharma research. International director Giacomo Ficari said at the Web Summit in Lisbon that science demands smarter AI models than law, finance, or code.
Beijing startup DP Technology is integrating Kimi K3.1 Pro into its research assistant BioMaster. In one test, the AI analyzed gene data from 3,696 mouse pancreatic cells and flagged 100 candidate genes in 90 minutes instead of an estimated four hours of human work.
Fully independent breakthroughs are still a long way off. On TCSExam, a 100-problem theoretical CS benchmark, leading models produced verifiable proofs but couldn't crack any open conjectures alone. US rivals hit similar limits. Anthropic's Claude found an enzyme system in September, but mathematicians criticized OpenAI's claimed math and physics breakthroughs. The pharma industry isn't sold yet either. A June Citi survey of 50 US research leaders found 72 percent already using AI broadly, but only 24 percent expect it to noticeably improve drug development success rates.